Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas E Witzig

Showing results (191-200 of 387) with videos related to

Pageof 39
Sort By:
Blood|July 15, 2009
B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disordersRyan A Wilcox, Andrew L Feldman, David A Wada, et al.
American Journal of Hematology|March 16, 2010
A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphomaPatrick B Johnston, David J Inwards, Joseph P Colgan, et al.
European Journal of Haematology|August 2, 2006
Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosisCarlo Visco, Gianpaolo Nadali, Theodoros P Vassilakopoulos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2009
Percentage of smudge cells on routine blood smear predicts survival in chronic lymphocytic leukemiaGrzegorz S Nowakowski, James D Hoyer, Tait D Shanafelt, et al.
Leukemia & Lymphoma|July 7, 2007
Subcutaneous interleukin-4 (IL-4) for relapsed and resistant non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group, NCCTG 91-78-51David M Kurtz, Loren K Tschetter, Jacob B Allred, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2002
Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphomaThomas E Witzig, Leo I Gordon, Fernando Cabanillas, et al.
Blood|May 31, 2002
Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trialGregory A Wiseman, Leo I Gordon, Pratik S Multani, et al.
Leukemia & Lymphoma|November 22, 2011
The absolute monocyte count is associated with overall survival in patients newly diagnosed with follicular lymphomaRyan A Wilcox, Kay Ristow, Thomas M Habermann, et al.
Leukemia & Lymphoma|February 20, 2014
Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphomaLuis F Porrata, Kay M Ristow, Thomas M Habermann, et al.
Scientific Reports|April 16, 2021
Epigenetic alteration contributes to the transcriptional reprogramming in T-cell prolymphocytic leukemiaShulan Tian, Henan Zhang, Pan Zhang, et al.
Pageof 39

Showing results (191-200 of 387) with videos related to

Sort By:
Pageof 39
Blood|July 15, 2009
B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disordersRyan A Wilcox, Andrew L Feldman, David A Wada, et al.
American Journal of Hematology|March 16, 2010
A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphomaPatrick B Johnston, David J Inwards, Joseph P Colgan, et al.
European Journal of Haematology|August 2, 2006
Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosisCarlo Visco, Gianpaolo Nadali, Theodoros P Vassilakopoulos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2009
Percentage of smudge cells on routine blood smear predicts survival in chronic lymphocytic leukemiaGrzegorz S Nowakowski, James D Hoyer, Tait D Shanafelt, et al.
Leukemia & Lymphoma|July 7, 2007
Subcutaneous interleukin-4 (IL-4) for relapsed and resistant non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group, NCCTG 91-78-51David M Kurtz, Loren K Tschetter, Jacob B Allred, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2002
Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphomaThomas E Witzig, Leo I Gordon, Fernando Cabanillas, et al.
Blood|May 31, 2002
Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trialGregory A Wiseman, Leo I Gordon, Pratik S Multani, et al.
Leukemia & Lymphoma|November 22, 2011
The absolute monocyte count is associated with overall survival in patients newly diagnosed with follicular lymphomaRyan A Wilcox, Kay Ristow, Thomas M Habermann, et al.
Leukemia & Lymphoma|February 20, 2014
Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphomaLuis F Porrata, Kay M Ristow, Thomas M Habermann, et al.
Scientific Reports|April 16, 2021
Epigenetic alteration contributes to the transcriptional reprogramming in T-cell prolymphocytic leukemiaShulan Tian, Henan Zhang, Pan Zhang, et al.
Pageof 39